Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
4.430
-0.010 (-0.23%)
At close: Nov 4, 2026, 4:00 PM EST
4.442
+0.012 (0.26%)
After-hours: Nov 4, 2026, 5:57 PM EST

Gyre Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22
4706421,0381,967-
Market Cap Growth
-33.27%-38.21%-47.22%--
Enterprise Value
3986181,0501,946-
Last Close Price
4.447.0612.1025.69-

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22
PE Ratio
-127.6585.93--
Forward PE
-32.84---
PS Ratio
4.285.509.8217.34-
PB Ratio
4.364.5110.5525.07-
P/TBV Ratio
4.556.4316.85--
P/FCF Ratio
---113.23-
P/OCF Ratio
-635.33-75.99-

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22
EV/Sales Ratio
3.635.309.9317.15-
EV/EBITDA Ratio
-44.1358.9695.72-
EV/EBIT Ratio
-53.8164.73101.27-
EV/FCF Ratio
---111.99-

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22
Debt / Equity Ratio
0.020.010.020.010.01
Debt / EBITDA Ratio
-0.060.090.020.06
Debt / FCF Ratio
---0.020.11
Net Debt / Equity Ratio
-0.43-0.36-0.25-0.42-0.34
Net Debt / EBITDA Ratio
5.88-3.67-1.41-1.63-2.38
Net Debt / FCF Ratio
11.69286.034.21-1.90-4.32
Asset Turnover
0.620.800.871.13-
Inventory Turnover
0.670.660.730.89-
Quick Ratio
3.594.582.642.493.33
Current Ratio
4.265.603.322.854.06
Return on Equity (ROE)
-17.44%8.21%20.24%-113.45%-
Return on Assets (ROA)
-5.42%4.93%8.38%11.93%-
Return on Invested Capital (ROIC)
-16.81%9.58%21.08%41.30%8.85%
Return on Capital Employed (ROCE)
-8.90%7.80%15.30%19.90%12.70%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22
Earnings Yield
-4.89%0.78%1.16%-4.72%-
FCF Yield
-1.30%-0.03%-0.57%0.88%-
Buyback Yield / Dilution
1.16%-0.87%-55.39%13.02%-
SEC Filings: 10-K · 10-Q